Diabetes

An 18-month Illinois pilot linking prison clinicians to endocrinologists via telehealth achieved a mean HbA1c reduction of 1.6 percentage points across 115 incarcerated men with diabetes.

ADA 2026 spotlighted triple incretin therapy, intensive LDL lowering, and the equity gaps that keep advances from reaching all patients.

New ADA 2026 data show diabetic ketoacidosis hospitalizations rising 24%, driven by poor ketone monitoring and symptom recognition gaps across all ages.

Orforglipron added to titrated insulin glargine reduced HbA1c at 40 weeks while producing clinically meaningful weight reductions.

The authors evaluated changes in persistence to basal insulin in a Medicare Advantage population in the first year of the Medicare insulin out-of-pocket cost cap.

Surgical therapy for diabetic gastroparesis was associated with meaningful reductions in HbA1c and lower rates of diabetes-related complications.

The approval is based on results from MannKind's phase 3 INHALE-1 clinical trial.

Consistent adherence to sodium-glucose cotransporter 2 (SGLT2) inhibitors in individuals with type 2 diabetes reduces the risk of hospitalization, supporting targeted interventions to improve medication-taking behavior.

High-dose vitamin D₃ supplementation reduced diabetes risk by 19% in adults with prediabetes who carry specific vitamin D receptor gene variants.

This study found high out-of-pocket costs for branded diabetes medications in employer-sponsored health plans.

Teplizumab-mzwv is the first disease-modifying therapy available for children as young as 1 year diagnosed with presymptomatic type 1 diabetes.

Receipt of an insurer-provided grocery benefit was associated with decreased rates of diabetes with complications and increased medication adherence among a population with diabetes.

The 2026 Regional Diabetes Summit is taking place from April 28 to 29, 2026, in Wilmington, Delaware.

The FDA has approved the first generic versions of dapagliflozin, expanding access to a widely used SGLT2 inhibitor.

The cap cut quarterly spending by the hundreds and lowered A1c levels but failed to expand the pool of insulin users.

Insulin icodec-abae (Awiqli; Novo Nordisk) is now approved for use in the US, Canada, European Union, Switzerland, and 12 other countries.

Findings show sustained reductions in HbA1c, weight, blood pressure, inflammation, and lipids in patients with T2D and ASCVD or CKD.

Insulin affordability improved for Medicare Part D beneficiaries between 2019 and 2023, with more paying $35 or less for a 30-day supply.

Predictive risk scores created using administrative claims and publicly available social determinants of health data strongly predicted severe diabetes complications for Maryland Medicare fee-for-service beneficiaries.

Study supports broader use of transient elastography to detect advanced liver fibrosis in patients with metabolic dysfunction–associated steatotic liver disease.

National data reveal increasing rates of type 1 and type 2 diabetes among children insured through Medicaid and CHIP.

Orforglipron achieved greater A1C reduction and weight loss than oral semaglutide, highlighting its potential as a needle-free option for type 2 diabetes.

The ready-to-use formulation supports clinicians and families by addressing historical administration challenges.

As utilization of GLP-1s grows for diabetes and weight management, out-of-pocket expenses and affordability concerns may affect broader health care policy discussions.

SGLT2 inhibitors were associated with significantly lower risks of kidney failure, cardiovascular events, mortality, and hepatic decompensation.